IBJNews

Lilly diabetes pill recommended for EU approval

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval in Europe, putting the drug on track to enter the region’s market this year.

The European Medicines Agency’s Committee for Medicinal Products for Human Use said Trajenta should be used in patients whose diabetes can’t be controlled by diet and exercise alone and who can’t take the older medication metformin, Boehringer said in a statement Friday.

Known chemically as linagliptin, the pill was approved in May by regulators in the U.S., where it’s marketed under the spelling Tradjenta. The drug is among four diabetes treatments Indianapolis-based Lilly and Ingelheim, Germany-based Boehringer agreed in January to develop and sell jointly, sharing equally in costs and margins from the products.

The drug can be an “important new treatment option” for patients with Type 2 diabetes, Enrique Conterno, president of Lilly’s diabetes division, said in the prepared statement.

The Boehringer partnership may contribute to earnings by 2014, Lilly said when the deal was announced. Sales of each drug may be about $2.84 billion, and combined peak sales may reach $14.2 billion, Engelbert Tjeenk Willink, the Boehringer executive responsible for human pharmaceutical products’ sales and marketing, said at the time.

More than 220 million people worldwide have diabetes, and about 90 percent have the Type 2 version, according to the World Health Organization. Obese people are among the most at risk for the disease, which prevents the body from using insulin properly to control blood glucose levels. Left untreated, Type 2 diabetes can lead to heart attack, stroke and blindness.

The European Medicines Agency, based in London, provides initial regulatory authorization for treatments from companies seeking regionwide approval in all European Union countries plus Iceland, Liechtenstein and Norway. The European Commission, the EU’s executive arm, gives final approval based on the agency’s recommendation.

Lilly stock fell 29 cents Friday morning, to $36.90 per share.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am not by any means judging whether this is a good or bad project. It's pretty simple, the developers are not showing a hardship or need for this economic incentive. It is a vacant field, the easiest for development, and the developer already has the money to invest $26 million for construction. If they can afford that, they can afford to pay property taxes just like the rest of the residents do. As well, an average of $15/hour is an absolute joke in terms of economic development. Get in high paying jobs and maybe there's a different story. But that's the problem with this ask, it is speculative and users are just not known.

  2. Shouldn't this be a museum

  3. I don't have a problem with higher taxes, since it is obvious that our city is not adequately funded. And Ballard doesn't want to admit it, but he has increased taxes indirectly by 1) selling assets and spending the money, 2) letting now private entities increase user fees which were previously capped, 3) by spending reserves, and 4) by heavy dependence on TIFs. At the end, these are all indirect tax increases since someone will eventually have to pay for them. It's mathematics. You put property tax caps ("tax cut"), but you don't cut expenditures (justifiably so), so you increase taxes indirectly.

  4. Marijuana is the safest natural drug grown. Addiction is never physical. Marijuana health benefits are far more reaching then synthesized drugs. Abbott, Lilly, and the thousands of others create poisons and label them as medication. There is no current manufactured drug on the market that does not pose immediate and long term threat to the human anatomy. Certainly the potency of marijuana has increased by hybrids and growing techniques. However, Alcohol has been proven to destroy more families, relationships, cause more deaths and injuries in addition to the damage done to the body. Many confrontations such as domestic violence and other crimes can be attributed to alcohol. The criminal activities and injustices that surround marijuana exists because it is illegal in much of the world. If legalized throughout the world you would see a dramatic decrease in such activities and a savings to many countries for legal prosecutions, incarceration etc in regards to marijuana. It indeed can create wealth for the government by collecting taxes, creating jobs, etc.... I personally do not partake. I do hope it is legalized throughout the world.

  5. Build the resevoir. If built this will provide jobs and a reason to visit Anderson. The city needs to do something to differentiate itself from other cities in the area. Kudos to people with vision that are backing this project.

ADVERTISEMENT